Potential limitations of activity tracking devices in monitoring effects of treatment for sarcoidosis.
Rebecca Klein(University of Cincinnati), Robert P. Baughman(University of Cincinnati), Nabeel Hamzeh(American Thoracic Society), Briana Barkes(National Jewish Health), T. Shivas(Pulmonary Fibrosis Foundation), Marc A. Judson(Cleveland Clinic), Dominique Valeyre(Inserm), Lisa A. Maier(National Jewish Health), Joyce Zeigler(University of Cincinnati), Nadera Sweiss(University of Illinois Chicago), Edward Chen(Johns Hopkins University), Daniel A. Culver(Cleveland Clinic), Noopur Singh(Pulmonary Fibrosis Foundation), Jan Grutters(St.-Antonius-Hospital Gronau), Ginger Spitzer(Pulmonary Fibrosis Foundation)
Cited by 3
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
|Immunity|2009|2.3k
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Sarcoidosis
|The Lancet|2013|1.1k
Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2020|1k